Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of AMPA glutamate receptor clustering. [GO_REF:0000058, GOC:hjd, GOC:TermGenie, PMID:21558424]
Regulation of AMPA glutamate receptor clustering is a complex and dynamic process that involves multiple molecular players and signaling pathways. It plays a crucial role in synaptic plasticity, the ability of synapses to strengthen or weaken in response to neuronal activity, which is essential for learning and memory.
AMPA receptors (AMPARs) are ionotropic glutamate receptors that mediate fast excitatory neurotransmission in the brain. Clustering of AMPARs at the postsynaptic membrane is essential for efficient synaptic transmission. This clustering is regulated by a balance of protein-protein interactions and post-translational modifications, which are influenced by neuronal activity.
**Key Players in AMPA Receptor Clustering:**
* **Scaffolding proteins:** PSD-95, SAP97, and SAP102 are scaffolding proteins that bind to the C-terminal tails of AMPAR subunits and link them to other postsynaptic proteins, including signaling molecules and the actin cytoskeleton.
* **Cytoskeletal proteins:** Actin filaments and associated proteins play a crucial role in anchoring AMPARs to the postsynaptic density (PSD), a specialized protein-rich region at the postsynaptic membrane.
* **Signaling molecules:** Several signaling pathways, including those involving calcium, protein kinases, and phosphatases, regulate AMPAR clustering. For example, calcium influx through NMDA receptors can activate calcium-dependent kinases, such as CaMKII, which phosphorylate AMPAR subunits and promote their insertion into the PSD.
* **Transporters and trafficking machinery:** AMPARs are continuously trafficked between intracellular compartments and the plasma membrane. Proteins like GluA2 and GluA3 are important for the trafficking of AMPARs.
* **Ubiquitin ligases and deubiquitinases:** These enzymes regulate the stability and degradation of AMPARs, thereby affecting their clustering.
**Mechanisms of Regulation:**
* **Phosphorylation:** Phosphorylation of AMPAR subunits by protein kinases, such as CaMKII and PKA, can enhance their surface expression and clustering.
* **Palmitoylation:** Palmitoylation, a type of lipid modification, can regulate AMPAR trafficking and clustering by affecting their interaction with the membrane and cytoskeletal proteins.
* **Ubiquitination:** Ubiquitination can target AMPARs for degradation or regulate their trafficking.
* **Activity-dependent trafficking:** AMPARs are dynamically trafficked in response to neuronal activity. Synaptic activity can promote the insertion of AMPARs into the PSD or their removal from the membrane.
**Regulation of AMPAR Clustering in Synaptic Plasticity:**
* **Long-term potentiation (LTP):** LTP, a form of synaptic plasticity associated with learning and memory, involves an increase in AMPAR clustering at synapses. This increase is mediated by the activation of signaling pathways, such as CaMKII and PKA, which promote AMPAR phosphorylation, trafficking, and clustering.
* **Long-term depression (LTD):** LTD, a form of synaptic plasticity associated with forgetting, involves a decrease in AMPAR clustering at synapses. LTD is often triggered by low-frequency stimulation and involves the activation of phosphatases that dephosphorylate AMPAR subunits, leading to their internalization and decreased clustering.
**Disruptions in AMPAR Clustering and Neurological Disorders:**
Disruptions in AMPAR clustering have been implicated in various neurological disorders, including:
* **Epilepsy:** Abnormal AMPAR clustering can contribute to hyperexcitability and seizures.
* **Schizophrenia:** Alterations in AMPAR expression and clustering have been linked to cognitive deficits in schizophrenia.
* **Alzheimer's disease:** Changes in AMPAR clustering have been observed in Alzheimer's disease, contributing to neuronal dysfunction.
**Summary:**
Regulation of AMPAR clustering is a critical process for maintaining synaptic function and plasticity. It involves a complex interplay of scaffolding proteins, cytoskeletal proteins, signaling molecules, and trafficking machinery. Disruptions in AMPAR clustering have been associated with a range of neurological disorders, highlighting the importance of understanding this process for developing therapeutic interventions.'
"
Protein | Definition | Taxonomy |
---|---|---|
Cystine/glutamate transporter | A cystine/glutamate transporter that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9UPY5] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
mesalamine | mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position. Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed) | amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols | non-steroidal anti-inflammatory drug |
sulfapyridine | sulfapyridine : A sulfonamide consisting of pyridine with a 4-aminobenzenesulfonamido group at the 2-position. Sulfapyridine: Antibacterial, potentially toxic, used to treat certain skin diseases. | pyridines; substituted aniline; sulfonamide; sulfonamide antibiotic | antiinfective agent; dermatologic drug; drug allergen; environmental contaminant; xenobiotic |
sulfasalazine | sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position. Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) | ||
cysteine | cysteine; cysteine zwitterion; L-alpha-amino acid; proteinogenic amino acid; serine family amino acid | EC 4.3.1.3 (histidine ammonia-lyase) inhibitor; flour treatment agent; human metabolite | |
quisqualic acid | Quisqualic Acid: An agonist at two subsets of excitatory amino acid receptors, ionotropic receptors that directly control membrane channels and metabotropic receptors that indirectly mediate calcium mobilization from intracellular stores. The compound is obtained from the seeds and fruit of Quisqualis chinensis. | non-proteinogenic alpha-amino acid | |
serine o-sulfate | L-serine O-sulfate : A non-proteinogenic L-alpha-amino acid that is the O-sulfo derivative of L-serine. serine O-sulfate: RN given refers to (L)-isomer | L-serine derivative; non-proteinogenic L-alpha-amino acid; O-sulfoamino acid | |
homocysteic acid | homocysteic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group has benn oxidised to the corresponding sulfonic acid. homocysteic acid: promotes growth in hypophysectomized rats; RN given refers to parent cpd L-homocysteic acid : A homocysteic acid with L-configuration. | homocysteic acid | NMDA receptor agonist |
susalimod | susalimod: analogue of sulphasalazine, was designed for use in the treatment of rheumatoid arthritis | ||
erastin | erastin : A member of the class of quinazolines that is quinazolin-4(3H)-one in which the hydrogens at positions 2 and 3 are replaced by 1-{4-[(4-chlorophenoxy)acetyl]piperazin-1-yl}ethyl and 2-ethoxyphenyl groups, respectively. It is an inhibitor of voltage-dependent anion-selective channels (VDAC2 and VDAC3) and a potent ferroptosis inducer. erastin: an antineoplastic agent; structure in first source | aromatic ether; diether; monochlorobenzenes; N-acylpiperazine; N-alkylpiperazine; quinazolines; tertiary carboxamide | antineoplastic agent; ferroptosis inducer; voltage-dependent anion channel inhibitor |